Are nonfunctioning adrenal incidentalomas really nonfunctioning? A retrospective single-center study.

Clinical guidelines often classify adrenal incidentalomas as nonfunctioning if cortisol levels remain low after specific suppression testing. However, the true physiological impact of these masses remains a subject of ongoing debate. Prior research has shown that some patients with these growths exhibit cardiovascular risks despite meeting standard criteria for normal hormone status. That uncertainty drove this investigation into whether these masses exert hidden influences on systemic blood pressure. No prior work had resolved if current diagnostic cut-offs effectively capture all instances of autonomic cortisol hypersecretion. This gap motivated a closer look at the prevalence of hypertension in this specific patient population. Understanding these potential subclinical effects is vital for refining endocrine screening protocols. The current study addresses this ambiguity by comparing patients with adrenal masses against a control cohort.

The primary aim of this study was to investigate the frequency of hypertension in patients diagnosed with nonfunctioning adrenal incidentalomas. Researchers sought to determine if these masses, currently classified as inactive, might contribute to systemic blood pressure issues. This investigation was motivated by the clinical observation that many patients with such growths exhibit cardiovascular risks despite normal hormone test results. The team aimed to challenge the assumption that these adrenal masses are truly nonfunctioning in terms of autonomic cortisol hypersecretion. By comparing these patients to a control group, they intended to uncover hidden physiological impacts. The study addresses the uncertainty surrounding current diagnostic cut-offs used to exclude hormonal activity. No prior work had fully resolved whether these thresholds effectively capture all clinically relevant cases. This research provides a necessary evaluation of whether current endocrine screening protocols adequately protect patient health.

This retrospective investigation compared patients with adrenal incidentalomas to a control group of individuals diagnosed with thyroid nodules. The research team collected data from an endocrinology clinic between September 2020 and May 2023. They carefully selected participants to ensure age and gender matching between the two cohorts. The study design focused on evaluating the frequency of high blood pressure across these distinct patient populations. Researchers employed binary logistic regression to identify independent variables influencing cardiovascular health outcomes. The review approach involved analyzing dexamethasone suppression test results to categorize hormonal activity levels. Statistical comparisons utilized specific p-values to determine the significance of observed differences in hypertension prevalence. This methodology allowed for a robust assessment of how adrenal masses might influence systemic blood pressure regulation.

The study found that hypertension occurred in 50.4% of the adrenal incidentaloma group, which was significantly higher than the 31.6% observed in the control group. Statistical analysis confirmed this difference with a p-value of 0.004. Patients with dexamethasone suppression test results of 0.87 μg/dL or higher showed a 66.1% hypertension frequency. In contrast, those with results below this threshold exhibited a 42.6% frequency, yielding a p-value of 0.009. Binary logistic regression identified age as an independent factor with an odds ratio of 1.07. The suppression test result also emerged as an independent predictor with an odds ratio of 3.24. These results suggest a clear association between adrenal mass presence and elevated blood pressure. The findings highlight that current diagnostic cut-offs may fail to identify all patients with autonomic cortisol hypersecretion.

The authors suggest that hypertension occurs more frequently in individuals diagnosed with nonfunctioning adrenal incidentalomas than in control populations. Their data indicate that current diagnostic thresholds for cortisol suppression might overlook subtle cases of autonomic cortisol hypersecretion. The researchers propose that these undetected hormonal shifts contribute to the observed cardiovascular disparities between groups. Statistical modeling identified both age and specific suppression test results as independent predictors of blood pressure status. These observations imply that the standard definition of nonfunctioning masses may require re-evaluation to improve patient management. The study highlights a potential link between adrenal incidentalomas and systemic vascular health that warrants further clinical attention. By identifying these independent risk factors, the team provides evidence for reconsidering how clinicians interpret borderline suppression test outcomes. Future clinical practice could benefit from lower diagnostic cut-offs to better identify patients at risk for hypertension.